25
PORTABLE MOLECULAR DIAGNOSIS OF HPV Catherine Klapperich, Ph.D. Director, Center for Future Technologies in Cancer Care Boston University

POCTRN Day 1 Klapperich

Embed Size (px)

Citation preview

Page 1: POCTRN Day 1 Klapperich

PORTABLEMOLECULARDIAGNOSISOFHPV

CatherineKlapperich,Ph.D.Director,CenterforFuture

TechnologiesinCancerCareBostonUniversity

Page 2: POCTRN Day 1 Klapperich

CervicalCancerandHPV

Whendiagnosedearlyandaccurately,cervicalcancerhasahigh5yearsurvivalrate,emphasizingthevalueofearlydetection.

Cervicalcanceristhefourthmostcommoncancerinwomenworldwideandkills266,000womenperyear.

Approximately87%ofthesecasesareindevelopingcountries,wheretherearelimitedresourcesforscreening.

HPVisthecausativeagentinmostcervicalcancers.

Page 3: POCTRN Day 1 Klapperich

WHOGuidelinesforCervicalCancerScreening

What happens if there’s a positive test? Where does this fit in to the treatment chain?

Page 4: POCTRN Day 1 Klapperich

ComponentsofaPortableMolecularDiagnostic

Sample Collection

Isolate nucleic acids

Amplify Nucleic Acids

Readout

Page 5: POCTRN Day 1 Klapperich

Cao Q et al., PLoS ONE 7(3): e33176. (2012)

• 146 NPA and NPS samples were collected during 2008-2010 at Boston Medical Center (BMC) Beth Israel Deaconess Medical Center (BIDMC).

• Patients presenting with one or more of: fever, cough, sore throat, myalgia, nasal congestion, headache, malaise, or diarrhea.

• 12 months to 70 years.

• RT-PCR Chip for INFLA

Page 6: POCTRN Day 1 Klapperich
Page 7: POCTRN Day 1 Klapperich

DesignforPOC– DesignforMinimalInstrumentation

• Size

• Shelflife

•Passiveflow

•Heatwithminimal/no

instrumentation

• Intuitivereadoutwithoutinstrumentation

Goal:Getamoleculartesttoaremoteclinic.

Page 8: POCTRN Day 1 Klapperich

NucleicAcidIsolation

Rodriguezetal.,Anal.Chem.,2015,87 (15),pp7872–7879

Page 9: POCTRN Day 1 Klapperich

ValidationofAmplifiableNAAnalysisofLAMPinDifferentPapers

Linnes JC, Rodriguez NM, Liu L, Klapperich CM, Biomed Microdevices. 2016 Apr;18(2):30.

Page 10: POCTRN Day 1 Klapperich

NucleicAcidAmplification

Isothermal Techniques LAMPHDA

Page 11: POCTRN Day 1 Klapperich

DNAExtractedfromStool,AmplifiedwithoutInstrumentation

HuangS,etal.(2013),PLoSONE8(3):e60059.

60-65°C

Page 12: POCTRN Day 1 Klapperich

Linnes,etal.,RSCAdv.2014Jan1;4(80):42245-42251.

Lysis,IsolationandAmplificationonPaperChlamydiaCells(DNA)

Page 13: POCTRN Day 1 Klapperich

Readout

Page 14: POCTRN Day 1 Klapperich

ClinicalInfluenzaASamples:IsothermalAmplificationandPaperReadout

Rodriguezetal.,Anal.Chem.,2015,87 (15),pp7872–7879

Page 15: POCTRN Day 1 Klapperich

IntegrationforHPV16DetectioninCervicalSwabSamples

Page 16: POCTRN Day 1 Klapperich

RunningtheChip

N.M.Rodriguez,etal.LabChip,2016,16,753-763

Page 17: POCTRN Day 1 Klapperich

Results

N.M.Rodriguez,etal.LabChip,2016,16,753-763

Page 18: POCTRN Day 1 Klapperich

MultiplexingHPV16andHPV18

Page 19: POCTRN Day 1 Klapperich

JaneDx,Inc.IncubatingattheBUPhotonicsCenter

Rajan Dewar, M.D. Catherine Klapperich, Ph.D. Mario Cabodi, Ph.D. Natalia Rodriguez, Ph.D.

Page 20: POCTRN Day 1 Klapperich

Customer&ValueChain• TargetCustomersandValueChainDynamics:

• USpathlabs/Consumerplay• GeneralstrategyforLMIC:

• Ministryofhealth• NGOs• Providers• Patients

• Firsttargetmarket: India• Privatepracticesanddistributorswillbuyfromusandselldirectlytopatients.• Wewillthustargetdistributors,privatepractice providers,thenstategovernment• distributors(price,performance)à users(price)

Page 21: POCTRN Day 1 Klapperich

RevenueModel&PotentialMarketSize:• Reimbursement: LMICmarketsarehighlysegmented:

• Insurance/reimbursementstructurenearlynon-existent(country-dependent)

• WillpatientspayOut-of-pocketfortests?• India:growingmiddleclasspays100%oopfortestsalready• Verysensitive toprice

• RevenuePotential:India• Customerswouldpay$10distributorspertest(assuming100%markup);distributorsbuyfromJaneDXat$5pertest.

• Screeningguideline:Womenages35– 64,cytologyevery3years;344millionwomenareeligible forscreening

• Test110millionwomeneveryyearà $550M/yearpotentialrevenue

21

Page 22: POCTRN Day 1 Klapperich

FeasibilityStudyLate2016

SriRamachandra

MedicalCollege

(MOU)

TamilNadu

JaneDx,Inc.

Boston,MA

1000patients,3monthPilot.IntegratedintoCurrentScreeningProgram.

Page 23: POCTRN Day 1 Klapperich

TamilNadu– PilotProgram

Totalnumberoftargetwomenscreened:2,91,525+1,96,559$1.5perpatient

MorewomendiefromcervicalcancereveryyearinIndia thananywhereelseintheworld,accordingtotheCervicalCancer-FreeCoalition

JaneDx

Page 24: POCTRN Day 1 Klapperich

POCTRNResourcesLeveraged

• CFTCCAlphaPrototypingCoretoMakeEarlyChipsforProofofConcept.

• CIMITPrimaryCareCenterPilotGrant• CIMITCRAASHCourseandMentorship• CFTCCClinicalNeedsAssessmentCoreforIndiaMarketResearch/ContactEstablishment.

• JHUSTICenterDiscussions/Mentorship/TrainingRe:SamplePreparationofCervicalSwabs.

Page 25: POCTRN Day 1 Klapperich

Acknowledgements Current Lab Members Dr. Andy FanDr. Sharon WongNatalia RodriguezWinnie WongLena LiuConstantinos KetavatisGeorge PrattProf. Mario Cabodi

AlumniDr. Jacqueline LinnesDr. Jason KellerDr. Cassandra NoackSamantha ByrnesDr. Jaephil DoMichelle Wong Dr. Mincheol Kim Dr. Shichu Huang Nga HoDr. Qingqing CaoDr. Sonali MahalanabisDr. Jane ZhangDr. Arpita BhattacharyyaJared SaffieJake TruebMelike Karakaya

NIH U54 EB015403NIH R01 EB008268NIH R44 AI073221NIH R21 AI071261NIH R41 AI092913

www.bu.edu/cftccwww.bu.edu/klapperich